The pharma company said the drug combined with eltrombopag demonstrated a significant improvement in time to treatment ...

Novartis AG said an experimental medicine helped patients with an autoimmune disease in late-stage studies, offering a boost ...

Novartis may have abandoned one Sjögren's syndrome asset this year, but it looks like the drugmaker has a winner on its hands ...

A mere 24 hours after Novartis' ianalumab hit the mark in two phase 3 trials in Sjogren's syndrome, the drug has delivered ...

Novartis' ianalumab plus eltrombopag significantly extended treatment response and improved platelet counts in a Phase 3 ...

A day after posting a pair of phase 3 wins for the tricky indication of Sjögren's syndrome, the Swiss pharma has unveiled a ...

Novartis announces positive results from VAYHIT2 phase III trial of ianalumab plus eltrombopag in patients with primary immune thrombocytopenia: Basel Wednesday, August 13, 2025, ...

Ianalumab prolonged the duration of safe platelet levels during and after treatment in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids1,2 Patients treated ...

The drug, ianalumab, met its objectives in two Phase 3 studies in Sjögren’s syndrome, boosting the outlook of a ...

Switzerland’s government has reached out to local drugmakers Roche Holding AG and Novartis AG to discuss the tariff situation ...

Novartis has been evaluating a bid for Avidity, which had a market value of about $5.8bn at market close on Wednesday, and ...

The German pharma will license a KRAS G12D inhibitor from Kumquat Biosciences. Elsewhere, a Biohaven OCD drug missed its ...